Status:
COMPLETED
Cell Surface Marker Expression in Autoimmune Diseases
Lead Sponsor:
Alpine Immune Sciences, Inc.
Conditions:
Systemic Lupus Erythematosus
Sjogren's Syndrome
Eligibility:
All Genders
19+ years
Brief Summary
This study is designed to explore the expression of cell-surface markers in the following seven disease areas: (a) systemic lupus erythematosus, (b) Sjogren's syndrome, (c) multiple sclerosis, (d) sys...
Eligibility Criteria
Inclusion
- Male or female participants 19 years of age or older.
- Participant or legal surrogate able and willing to provide written, informed consent.
- Participant is, or has been undergoing care for one of the specified diseases in a participating centre with a confirmed clinical diagnosis of the specified disease.
- Participant has or will provide the relevant peripheral blood (required) and normal practice tissue specimens (if available).
- Participant has one of the following target auto-immune or inflammatory diseases diagnosed according to local clinical practice guidelines:
- Crohn's Disease
- Inflammatory myositis
- Multiple sclerosis
- Sjogren's syndrome
- Systemic lupus erythematosus
- Systemic sclerosis
- Ulcerative colitis
Exclusion
- Participants receiving investigational therapy within 30 days or 5 half-lives, whichever is longer, prior to enrolment.
- Participants suffering from any additional disease that may interfere with the biomarker signals as per the investigator's discretion.
Key Trial Info
Start Date :
June 12 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 25 2019
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT03757065
Start Date
June 12 2019
End Date
October 25 2019
Last Update
August 27 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
GI Research Institute
Vancouver, British Columbia, Canada, V6Z 2K5
2
Mary Pack Arthritis Center
Vancouver, Canada